瑞舒伐他汀治疗ST段抬高急性心肌梗死患者的疗效及量效关系研究

Treatment effect and dose-effect relationship of rosuvastatin in patients with ST-segment elevation acute myocardial infarction

目的研究瑞舒伐他汀治疗ST段抬高急性心肌梗死患者的疗效及量效关系。方法纳入我院于2015年1月~2016年1月收治的76例ST段抬高急性心肌梗死患者为研究对象,将患者抽签随机分为观察组与对照组各38例。观察组口服瑞舒伐他汀20 mg/d,对照组口服瑞舒伐他汀10 mg/d,两组患者均连续治疗2个月。对比两组超敏C反应蛋白(hs-CRP)、脑钠肽(BNP)、白细胞介素-6(IL-6)水平变化,记录左室收缩末径(LVESD)、舒张末径(LVEDD)和左室射血分数(LVEF)等心功能参数及不良反应发生率。结果两组治疗后hs-CRP、BNP、IL-6水平低于治疗前,且观察组低于对照组(P<0.05)。两组治疗后LVESD、LVEDD均低于治疗前,LVEF高于治疗前(P<0.05)。观察组治疗后LVESD、LVEDD低于对照组,LVEF高于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论瑞舒伐他汀治疗ST段抬高急性心肌梗死疗效较好,安全性高,可有效抑制患者心室重构,改善心功能,且增加药物剂量可提高疗效。

Ohjective To study the efficacy and dose-effect relationship of rosuvastatin in patients with ST-segment elevation acute myocardial infarction. Methods 76 patients with ST-segment elevation acute myocardial infarction in our hospital were enrolled from Jan, 2015 to Jan, 2016. The patients were randomly divided into observation group（n=38） and control group （n=38） according to lottery method. The observation group was given orally rosuvastatin 20 mg/d, and the control group was treated with oral administration of rosuvastatin I0 mg/d. Two groups of patients were treated for 2 months. The levels of high-seosit!vity C--reactive protein （hs-CRP）, brain natriuretic peptide（BNP）, intedeukin-6（IL-6） were compared between the two groups. Apd the cardiac function parameters including left ventricular systolic diameter （LVESD）, left vgntrieular end,diastolic diameter （LVEDD） and left ventricular ejection fraction （LVEF） as well as the incidence of adverse reactiona were recorded. Results The levels of hs-CRP, BNP and IL-6 in the two groups after treatment were lower than those before treatment, and the above indicators in the observation group were lower than those in the control g（oup（P〈0.05）. LVVED and LVEDD in the two groups after treatment were lower than those before treatment, and LVEF after treatment was higher than that before treatment（P〈0.05）. LVESD and LVEDD were lower in the observation group than those in the control gro^ap, and LVEF was higher in the observation group than that in the control group（P〈O.05）. There was no significant difference in the incidence of adverse reactions between the two groups （P〉0.05）. Conclusion Rosuvastatin is effective in the treatment of ST-segment elevation acute myocardial infarction with high safety, which is effective in suppressing ventricular remodeling and improving cardiac function, and increas- ing the dose can improve the curative effect.